Allergic rhinitis (AR) is a common condition that affects millions of people worldwide. It is characterized by inflammation of the nasal lining due to an allergic reaction to environmental allergens such as pollen, dust mites, and animal dander. Symptoms of AR include sneezing, runny nose, nasal congestion, and itching, which can have a significant negative impact on the patient's quality of life. A clinical trial investigated the efficacy of Montelukast and intranasal antihistamine in combination with intranasal corticosteroid (INCS) in moderate to severe AR on the patient's quality of life and AR control.
The study was a double-blind randomized clinical trial that was carried out on 66 moderate to severe AR patients from 2020 to 2021. The patients were randomly divided into three groups. Group one received Montelukast add-on therapy and Budesonide nasal spray. The second group received intranasal antihistamine (Azelastine) add-on therapy and Budesonide nasal spray, and the third group was the control group and received intranasal Budesonide spray with a placebo tablet.
To measure the impact of each medication on the patient's quality of life and allergic rhinitis control, the Sino-Nasal Outcome Test-22 questionnaire (SNOT 22) was used. The patient's symptoms were evaluated and compared at baseline, one and three months after the start of treatments. Spirometry was performed to investigate the possibility of co-morbid asthma at baseline and end of the study.